Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 38.1% on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. 605,625 shares were traded during trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Trading Up 20.0 %
The stock has a market capitalization of C$20.91 million, a P/E ratio of -12.00 and a beta of 0.20. The company has a 50-day moving average price of C$0.09 and a two-hundred day moving average price of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Most Volatile Stocks, What Investors Need to Know
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
